Dated: August 20, 2001.

#### Yvonne T. Maddox,

Acting Deputy Director, National Institutes of Health.

[FR Doc. 01–21778 Filed 8–28–01; 8:45 am] BILLING CODE 4140–01–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### **National Institutes of Health**

## Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health, Public Health Service, HHS.

**ACTION:** Notice,

SUMMARY: The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by contacting Dale D. Berkley, Ph.D., J.D., at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/496–7735 ext. 223; fax: 301/402–0220; e-mail: berkleyd@od.nih.gov. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

### Generalized MRI Artifact Reduction Using Array Processing Method

Peter Kellman, Elliott McVeigh (NHLBI) DHHS Reference No. E–198–00/0 filed 03 Apr 2001

The invention is a phased array combining method for reducing artifacts in Magnetic Resonance (MR) imaging. The method uses a constrained optimization that optimizes signal-tonoise subject to the constraint of nulling ghost artifacts at known locations. The method is effective in reducing or canceling artifacts that arise in a wide variety of MR applications, including ghost artifacts from echo planar imaging and Gradient Recalled Echo with Echo Train (FGRE–ET) imaging used in cardiac or other rapid imaging applications. The strategy of using phase encode acquisition orders with distortion that results in ghosts,

followed by applying this phased array ghost cancellation method has a number of benefits, including reduced blur and geometric distortion, reduced acquisition time (eliminating echo shifting), and reduced sensitivity to flow.

#### E-Portals in Commerce (E-PIC)

Diana V. Mukitarian (OD) DHHS Reference No. E-147-00/0

The invention is a consolidated database for storing and maintaining vendor contact information and contract services that each can offer. The purpose of the invention is to consolidate vendor sources into one database, enabling vendors to easily add and update their contact information, to provide a variety of search criteria for providing sources for an organization's acquisitions, and to make such a system user friendly and available to the organization administrators. The system serves as a gateway for the business community to gain access to the organization's contracts and allows the organization to follow the acquisition cycle at every step. The database is designed to serve as a center for all communication for any service vendor seeking to do business with the organization. At any time an administrator can visit the repository to look for approved contractors and review their performance on past projects, with the intention of seeking proposals for work via an automated process. For more information, please direct your web browser to http:// sbo.od.nih.gov/epicfactsheet.pdf.

Dated: August 20, 2001.

### Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 01–21780 Filed 8–28–01; 8:45 am] BILLING CODE 4140–01–P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

### **National Institutes of Health**

# National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose

confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel, Program Project Application.

*Date:* October 3–5, 2001.

Time: 5 p.m. to 12 p.m.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn—Georgetown, 2101 Wisconsin Avenue, N.W., Washington, DC 20007.

Contact Person: Raymond A. Petryshyn, PhD, Scientific Review Administrator, Grants Review Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Blvd., 8th Fl. Room 8133, Bethesda, MD 20892, 301/594–1216.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: August 21, 2001.

### Laverne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 01–21771 Filed 8–28–01; 8:45 am] **BILLING CODE 4140–01–M** 

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

### **National Institutes of Health**

# National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial

property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel, Review and Analysis of Tobacco Industry Documents.

Date: September 14, 2001. Time: 8:30 a.m. to 2:30 p.m.

Agenda: To review and evaluate grant applications.

*Place:* Holiday Inn, 5520 Wisconsin Ave, Chevy Chase, MD 20815.

Contact Person: Gerald G. Lovinger, PhD., Scientific Review Administrator, Grants Review Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, Room 8101, Rockville, MD 20892—7405, 301/496—7987.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: August 21, 2001.

### LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 01–21772 Filed 8–28–01; 8:45 am]

BILLING CODE 4140-01-M

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

### **National Institutes of Health**

# National Center for Complementary and Alternative Medicine; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Institute Council for Complementary and Alternative Medicine.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other

reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Council for Complementary and Alternative Medicine.

Date: August 27, 2001.

Open: 8:30 a.m. to 5 p.m.

Agenda: The agenda will include a Center Initiative Update, an Interim Report of the White House Commission on CAM Policy, and other business of the Council.

Place: Neuroscience Conference Center, 6001 Executive Boulevard, Conference Room C and D, Rockville, MD 20852.

Closed: 3 p.m. to Adjournment. Agenda: To review and evaluate grant applications.

Place: Neuroscience Conference Center, 6001 Executive Boulevard, Conference Room C and D, Rockville, MD 20852.

Contact Person: Jane F. Kinsel, National Center for Complimenary Medicine, National Institutes of Health, 9000 Rockville Pike, Building 31, Room 5B38, Bethesda, MD 20892, (301) 435–5042, kinselj@mail.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: nccam.nih.gov/nccam/an/advisory/index.html, where an agenda and any additional information for the meeting will be posted when available.

Dated: August 21, 2001.

### LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 01-21770 Filed 8-28-01; 8:45 am]

BILLING CODE 4140-01-M

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

### **National Institutes of Health**

# National Institute of Allergy and Infectious Diseases; Notice of Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of meetings of the National Advisory of Allergy and Infectious Diseases Council.

The meetings will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Allergy and Infectious Diseases Council Allergy, Immunology and Transplantation Subcommittee.

Date: September 24, 2001.

Closed: 8:30 AM to 11 AM.

*Agenda:* To review and evaluate grant applications.

*Place:* Natcher Building, 45 Center Drive, Bethesda, MD 20892.

Open: 12:15 PM to adjournment. Agenda: Open program advisory discussions and presentations.

Place: Natcher Building, 45 Center Drive, Bethesda, MD 20892.

Contact Person: John J. McGowan, Director, Division of Extramural Activities, NIAID, Room 2142, 6700–B Rockledge Drive, MSC 7610, Rockville, MD 20892–7610, 301–496– 7291.

Name of Committee: National Advisory Allergy and Infectious Diseases Council Microbiology and Infectious Diseases Subcommittee.

Date: September 24, 2001.

Closed: 8:30 AM to 11 AM.

Agenda: To review and evaluate grant applications.

Place: Natcher Building, 45 Center Drive, Conference Room F1/F2, Bethesda, MD 20892.

Open: 12:15 PM to adjournment. Agenda: Open program advisory discussions and presentations.